


 Cite this: *RSC Adv.*, 2023, **13**, 8743

Antiviral activity of amide-appended α -hydroxytropolones against herpes simplex virus-1 and -2[†]

 Andreu Gazquez Casals,^{‡a} Alex J. Berkowitz,^{‡bc} Alice J. Yu,^a Hope E. Waters,^a Daniel V. Schiavone,^{bc} Diana M. Kapkayeva,^b Lynda A. Morrison^{*a} and Ryan P. Murelli^{id *bcd}

α -Hydroxytropolones (α HTs) have potent antiviral activity against herpes simplex virus-1 and -2 (HSV-1 and HSV-2) in cell culture, including against acyclovir-resistant mutants, and as a result have the potential to be developed as antiviral drugs targeting these viruses. We recently described a convenient final-step amidation strategy to their synthesis, and this was used to generate 57 amide-substituted α HTs that were tested against hepatitis B virus. The following manuscript describes the evaluation of this library against HSV-1, as well as a subset against HSV-2. The structure–function analysis obtained from these studies demonstrates the importance of lipophilicity and rigidity to α HT-based anti-HSV potency, consistent with our prior work on smaller libraries. We used this information to synthesize and test a targeted library of 4 additional amide-appended α HTs. The most potent of this new series had a 50% effective concentration (EC₅₀) for viral inhibition of 72 nM, on par with the most potent α HT antivirals we have found to date. Given the ease of synthesis of amide-appended α HTs, this new class of antiviral compounds and the chemistry to make them should be highly valuable in future anti-HSV drug development.

 Received 25th October 2022
 Accepted 28th February 2023

DOI: 10.1039/d2ra06749h

rsc.li/rsc-advances

Introduction

More than half of the U.S. population suffers from infection with herpes simplex virus (HSV-1),¹ and two thirds of people worldwide.² This large double-stranded DNA virus replicates in the oral or corneal epithelium, causing painful ulcerative lesions. HSV-1 is also beginning to supplant the related HSV-2 as the principal cause of sexually transmitted ulcerative disease of the genital epithelium.³ HSV enters sensory nerve endings innervating the epithelia and establishes life-long latent infection in nerve cell bodies within sensory ganglia. Periodic reactivations lead to reappearance of disease in the epithelium, which manifests as cold sores, sight-threatening

keratitis or, in the rare event of virus spread into the central nervous system, potentially lethal encephalitis. In addition, babies born to mothers shedding virus from the genital epithelium are at risk for disseminated HSV infection that induces high rates of morbidity and mortality.⁴ Although anti-HSV drug therapies exist they are incompletely effective⁵ and can drive emergence of resistant viruses.⁶ As a result, there is substantial interest in developing new and novel antivirals for HSV-1.⁷ Some of the novel enzyme and protein targets for HSV drug development include helicase–primase,⁸ thymidine kinase,⁹ and glycoprotein B.¹⁰

HSV-1 has a variety of divalent magnesium-based nucleases that are important for replication and infection and could be targeted by molecules possessing metal-binding fragments.¹¹ One such family of molecules possessing a metal-binding fragment is α -tropolones,¹² which have been of broad interest in drug development over the last few decades.¹³ α -Tropolones are known to be potent inhibitors of HSV-1 and -2,¹⁴ and this activity may be due to viral nuclease inhibition. For example, a sub-class of tropolones called α -hydroxytropolones (α HTs, *e.g.* 5, Scheme 1)¹⁵ are known to inhibit two magnesium-dependent HSV-1 enzymes, UL15 (ref. 16) and UL12,¹⁷ that are attractive targets for antiviral development. pUL15 is essential for viral DNA packaging,¹⁸ and disruption of its cytomegalovirus homologue pUL89 was validated clinically by letermovir

^aDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA. E-mail: andreu.gazquez@health.slu.edu; alice.yu@slu.edu; hope.waters@slu.edu; lynda.morrison@health.slu.edu

^bDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, NY, USA. E-mail: alex.berkowitz@brooklyn.cuny.edu; daniel.schiavone@brooklyn.cuny.edu; kapkayeva@gmail.com


^cPhD Program in Chemistry, The Graduate Center, The City University of New York, New York, NY, USA

^dPhD Program in Biochemistry, The Graduate Center, The City University of New York, New York, NY, USA

[†] Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2ra06749h>

[‡] Authors contributed equally.





Scheme 1 Synthetic routes to ketone and amide-appended α HTs.

prevention of infection.¹⁹ Meanwhile, HSV-1 pUL12 has alkaline nuclease activity essential for *in vivo* function.²⁰

One challenge associated with developing α HTs as drugs has been the scarcity of synthetic methods available to make structural variants of them,²¹ and up until very recently²² all synthetic chemistry-driven structure–function studies on the chemotype relied on direct modification of either 3,7-dihydroxytropolone²³ or manicol.²⁴ Of late, oxidopyrylium cycloaddition/ring-opening strategies have emerged that are highly effective for α HTs synthesis²⁵ and the strategy has been exploited in various medicinal chemistry-based pursuits, including against HSV-1 and -2.²⁶ One key study focused on ketone-appended α HTs, which demonstrated a strong correlation between lipophilicity and anti-HSV efficacy²⁷ and led to the discovery of a molecule with an EC_{50} of 60 nM (**5**, Scheme 1). The synthesis of this ketone library was not ideal for generating libraries of molecules, however, as each appendage often had to be tracked back to its associated ynone, which itself would often have to be made in one or two steps (top, Scheme 1). Thus, for each new α HT that is desired, as many as 5 steps are needed from the nearest common starting material. In addition, the final steps of the synthetic route are extremely harsh (usually triflic acid followed by hydrobromic acid in acetic acid, as shown), which limits the types of groups that can be installed. Thus, in pursuit of strategies more conducive to α HT library synthesis, amide-appended α HTs have been explored, which can be made through a final-step amidation strategy (bottom, Scheme 1).²⁸ A major advantage of this approach is that diversity is generated in the final step, allowing for larger and more diverse libraries. Consequently, a library of 57 amide-appended α HTs was recently generated and assessed against hepatitis B virus, *Cryptococcus neoformans*, and various bacteria.²⁹ Given the potential of α HTs as a valuable chemotype for anti-HSV development, and the practical benefits to amide-appended α HTs for

library synthesis, studies on the anti-HSV activity of amide-appended α HTs was pursued.

Results and discussion

57 amide-appended α HTs previously reported²⁹ were assessed for capacity to suppress viral replication at 50 μM and 5 μM , and active compounds (along with several inactive compounds) were also tested at 1 μM (Table 1). For clarity, these are reported based upon class through which they are subdivided. Thus, those derived from aniline are reported in Table 1A, benzylamine in Table 1B, piperidine/piperazine in Table 1C, amino acids in Table 1D, and a series of miscellaneous compounds that do not fall within any of these categories are in Table 1E. For further assistance with analysis, these are ordered based upon lipophilicity measurement ($c \log P$, determined with ChemDraw Professional, Version 16.0),³⁰ which is calculated in the monoanionic form that is expected at physiological pH³¹.

Lipophilicity was important for activity against HSV-1. The vast majority of molecules were capable of substantial inhibition of HSV-1 replication at a concentration of 50 μM ; only 5 of the 57 molecules tested did not suppress the virus by at least 10-fold (*i.e.*, $\log_{10} > 1.0$) at that concentration (see entries 22, 36 and 45–47, Table 1). At the lower concentration of 5 μM , however, less than half of the library was capable of suppressing, and lipophilicity highly correlated with this activity (Fig. 1A). Specifically, only two out of the 32 molecules with $c \log P$ values under -3.0 showed any appreciable antiviral activity ($\log_{10} > 1.0$) at 5 μM . Conversely, all 5 molecules with $c \log P$ values greater than -1.0 showed strong viral suppression ($\log_{10} > 3.0$). When evaluating molecules at 1 μM , the lipophilicity threshold for suppression $\log_{10} > 1.0$ increased to a $c \log P$ of roughly -1.3 (Fig. 1B). Specifically, all of the 32 molecules tested at this concentration that had a $c \log P$ less than -1.3 suppressed viral replication less than 1.0 \log_{10} . Meanwhile, all 6 molecules with $c \log P$ values greater than -1.3 inhibited replication by at least 1.0 \log_{10} . None of these 6 molecules demonstrated any significant anti-hepatitis B virus activity in prior studies,²⁹ with EC_{50} values (1.7–5.6 μM) comparable to their host cell-specific cytotoxicity ($CC_{50} = 3.3$ –8.7 μM). Furthermore, of the 16 α HT amides with previously reported hepatitis B antiviral EC_{50} values below 1 μM , only one (**53**, α HT-384) suppressed HSV-1 replication by 10 fold at 5 μM . Thus, the antiviral activity has some virus-based selectivity.

These 6 molecules with $c \log P$ values greater than -1.3 , as well as 9 other α HTs, were also tested against HSV-2. Their ability to inhibit HSV-2 replication at 5 μM or 1 μM tracked closely with the molecules' activity against HSV-1 (Fig. 2A vs. Fig. 2B). For example, 3 of the 6 potent inhibitors of HSV-1 at 1 μM were capable of inhibiting HSV-2 replication at the same concentration. Only 1 molecule tested did not inhibit HSV-1 replication at 1 μM but could inhibit HSV-2 at that concentration (**9**, α HT-834, Fig. 2B). Thus, amide-appended α HTs are also capable of potentially suppressing replication of the closely related HSV-2. In addition, synthetic α HTs can inhibit drug-resistant HSV mutants.^{6d} To ensure that amide-appended α HTs also inhibit drug-resistant virus, 3 of the 6 potentially inhibitory



Table 1 HSV-1-associated antiviral activity. +, modest reduction in cytopathic effect compared to DMSO control; –, no change in cytopathic effect; T, visual toxicity; nd, not determined















Entry	Amide (#) name	HSV-1 log suppression		Lipophilicity	
		50 μ M	5 μ M	1 μ M	$c \log P$
(A) Aniline-based amides					
1	 (6) α HT-711	+	–	–	–3.28
2	 (7) α HT-389	5.98	0.43	nd	–2.97
3	 (8) α HT-835	5.55	5.23	0	–1.87
4	 (9) α HT-834	4.67	1.8	–	–1.77
5	 (10) α HT-837	4.88	4.09	–	–1.28
6	 (11) α HT-836	4.35	5.2	3.15	–1.28
7	 (12) α HT-799	+	5.48	1.96	–0.9
8	 (13) α HT-798	+	5.61	1.82	–0.9
(B) Benzyl amine-based amide					
9	 (14) α HT-806	+	–	–	–2.87
10	 (15) α HT-388	5.23	0.05	nd	–2.79
11	 (16) α HT-1019	5.11	2.29	0.29	–2.51
12	 (17) α HT-809	+	2.78	0	–1.84
13	 (18) α HT-804	+	1.23	–0.14	–1.76
14	 (19) α HT-539	T	5.29	4	–0.9

Table 1 (Contd.)





















Entry	Amide (#) name	HSV-1 log suppression		Lipophilicity	
		50 μ M	5 μ M	1 μ M	$c \log P$
15	 (20) α HT-807	+	5.73	1.4	–0.69
(C) Piperazine and piperidine-based amide					
16	 (21) α HT-1016	5.35	0.73	nd	–5.51
17	 (22) α HT-918	1.01	0.19	0.02	–4.83
18	 (23) α HT-391	2.32	0.29	nd	–4.2
19	 (24) α HT-800	+	–	–	–4.16
20	 (25) α HT-802	+	–	–	–3.97
21	 (26) α HT-803	+	–	–	–3.72
22	 (27) α HT-871	0.81	–0.02	–0.1	–3.57
23	 (28) α HT-390	5.75	0.52	nd	–3.48
24	 (29) α HT-877	4.21	0.17	–0.24	–3.42
25	 (30) α HT-917	5.04	0.57	0.06	–3.18
26	 (31) α HT-920	1.49	–0.16	0.1	3.15
27	 (32) α HT-872	7.04	0.64	–0.03	2.89



Table 1 (Contd.)

Entry	Amide (#) name	HSV-1 log suppression		Lipophilicity	
		50 μ M	5 μ M	1 μ M	$c \log P$
28	 (33) α HT-876	6.92	0.28	-0.07	2.83
29	 (34) α HT-875	6.92	1.32	-0.25	-2.62
30	 (35) α HT-873	6.21	0.2	-0.15	-2.53
31	 (36) α HT-404	2.18	-	-	-2.163
32	 (37) α HT-919	5.28	6.07	0.84	-1.63
33	 (38) α HT-1021	5.84	1.77	0.23	-1.36
34	 (39) α HT-1020	5.21	0.36	nd	-1.17
35	 (40) α HT-1017	6.48	5.49	5.03	-0.59

(D) Amino acid-based amide





36	 (41) α HT-868	0.26	0.04	-0.15	-5.54
37	 (42) α HT-796	+	-	-	-4.29
38	 (43) α HT-793	+	-0.41	-	-3.51
39	 (44) α HT-797	+	-	-	-3.03

Table 1 (Contd.)



















Entry	Amide (#) name	HSV-1 log suppression		Lipophilicity	
		50 μ M	5 μ M	1 μ M	$c \log P$
40	 (45) α HT-795	+	-	-	-3.02
41	 (46) α HT-794	+	-	-	-2.99
42	 (47) α HT-867	5.21	5.91	0.16	-2.48
43	 (48) α HT-869	5.49	-0.14	nd	-1.76
44	 (49) α HT-870	5.34	-0.81	nd	-1.75
(E) Other amides					
45	 (50) α HT-709	-	-	-	-5.09
46	 (51) α HT-1018	0.51	-0.03	nd	-4.93
47	 (52) α HT-707	-	-	-	-4.32
48	 (53) α HT-384	4.49	1.04	0.36	-4.19
49	 (54) α HT-712	+	-	-	-3.73
50	 (55) α HT-808	+	-	-	-3.7
51	 (56) α HT-1039	4.57	2.95	0.23	-3.17
52	 (57) α HT-801	+	-	-	-3.14
53	 (58) α HT-874	2.41	-0.15	nd	-2.72



Table 1 (Contd.)

Entry	Amide (#) name	HSV-1 log suppression		Lipophilicity	
		50 μM	5 μM	1 μM	$c \log P$
54	 (59) $\alpha\text{HT-710}$	4.86	0.04	0.06	-2.66
55	 (60) $\alpha\text{HT-805}$	+	-	-	-2.59
56	 (61) $\alpha\text{HT-708}$	+	-	-	-2.28
57	 (62) $\alpha\text{HT-810}$	+	-	-	-1.73

molecules (**19**, $\alpha\text{HT-539}$; **40**, $\alpha\text{HT-1017}$; and **20**, $\alpha\text{HT-807}$) were tested against a mutant of HSV-1 resistant to acyclovir (ACV) (Fig. 2C). Whereas ACV inhibited only the wild-type virus, the three amide-appended αHTs strongly inhibited both wild-type and ACV-resistant viruses. This result suggests amide-appended αHTs could eventually be therapeutically useful in patients with nucleoside analogue-resistant infections.




Fig. 1 Correlation between lipophilicity and antiviral activity of amide-appended αHTs at (A) 5 μM and (B) 1 μM . Red-shaded points in (A) correspond to 6 molecules shaded and numbered red in (B). Molecules showing no viral suppression but not quantitated ('-' in Table 1) are denoted as '0' for graphical purposes.














Fig. 2 HSV replication inhibition at constant concentration. HSV-1 (A) vs. HSV-2 (B) replication inhibition of select αHTs . (C) Inhibition of αHTs and acyclovir (ACV) against wild-type HSV-1 and an acyclovir-resistant mutant (TK-). Data shown are the average and standard deviation of duplicate wells from a representative experiment.

The 6 most potent molecules were also evaluated more quantitatively to determine EC_{50} and CC_{50} values (Table 2A). The two most powerful inhibitors, $\alpha\text{HT-798}$ and $\alpha\text{HT-539}$ (**13** and **19**, entries 3 and 4), were isomeric, and both possessed *para* substitution patterns. The only difference was the placement of the methylene linker on one side of the aryl ring or the other. $\alpha\text{HT-799}$ (**12**), another isomer, was 6-fold less potent (entry 2). Thus, placements of substituents on the ring appear to be important for the higher activity. This trend for *para* preference was also observed with ether-containing molecules $\alpha\text{HT-807}$ (**20**) and $\alpha\text{HT-836}$ (**11**), although these were closer in activity to one another (entries 5 and 1). Finally, $\alpha\text{HT-1017}$ (**40**) was the only piperazine-containing molecule to be among the most potent molecules (entry 6), and also showed potency on par with $\alpha\text{HT-798}$ (**13**) and $\alpha\text{HT-539}$ (**19**). Some modest cytotoxicity was observed against the host cell line, Vero, after 48 h for some of the molecules. However, even in these instances, selectivity indexes were all in excess of 100.

Finally, with confirmation that amide-appended αHTs could serve as potent anti-HSV agents, and close correlation between this activity and lipophilicity, we sought to make a targeted library of 4 αHTs with enhanced lipophilicity (Table 2B). In addition, 3 of the molecules were designed to have limited rotational freedom (entries 7, 8 and 10). Consistent with our expectation that these would be potent antivirals against HSV-1, all 4 molecules inhibited viral replication $> 1.0 \log_{10}$ at a 1 μM concentration (data not shown). The most potent of the



Table 2 50% effective concentration for antiviral activity (EC₅₀) and Vero cytotoxicity (CC₅₀) measurements. Mean and standard error of the mean were calculated from 3 to 4 independent runs (EC₅₀) and 2 to 4 independent runs (CC₅₀)

Entry	Amide (#) name	HSV-1 EC ₅₀ (μM) ± SD	Vero CC ₅₀ (μM) ± SD	Selectivity CC ₅₀ /EC ₅₀	Lipophilicity (<i>c log P</i>)
(A) Top molecules to emerge from repurposing studies on 57 amide αHTs					
1	 (11) αHT-836	0.824 ± 0.264	29.6 ± 5.2	36	-1.28
2	 (12) αHT-799	1.274 ± 0.227	>100	>83	-0.9
3	 (13) αHT-798	0.217 ± 0.048	31.6 ± 6.1	140	-0.9
4	 (19) αHT-539	0.251 ± 0.059	90.2 ± 7.4	360	-0.9
5	 (20) αHT-807	0.462 ± 0.106	>100	>213	-0.69
6	 (40) αHT-1017	0.326 ± 0.024	49.5 ± 7.8	152	-0.59
(B) Newly created amide αHTs with increased lipophilicity					
7	 (63) αHT-1435	0.244 ± 0.097	74.2 ± 8.7	304	-0.157
8	 (64) αHT-1436	0.072 ± 0.021	75.7 ± 5.3	1050	0.425
9	 (65) αHT-1437	0.306 ± 0.016	92.5 ± 7.5	302	0.322
10	 (66) αHT-1438	0.296 ± 0.054	23.7 ± 3.8	80	0.184

molecules tested was αHT-1436 (**64**, entry 8), with an EC₅₀ measurement of 72 nM, in line with the most potent anti-HSV αHT we have described to date (5, αHT-360, Fig. 1). Cytotoxicity after 48 h remained low, providing a selectivity index for αHT-1436 (**64**) of over 1000. αHT-1436 (**64**) was the most lipophilic molecule tested, but was also highly rigid, with only a single rotatable bond on its amide appendage.

Structure–function studies on amide-appended αHTs provide additional data that demonstrates a close correlation between αHT lipophilicity and their potency against HSV. It remains unclear why this is the case, although when considering highly lipophilic anti-HSV agents, one must note 1-

docosanol, an active ingredient in the over-the-counter cold sore medication Abreva. It is believed that the activity of 1-docosanol may be related to its disruption of viral fusion with the cell membrane,³² though we have previously demonstrated no impact of αHTs on viral infectivity.¹⁴ A close correlation also exists between lipophilicity and anti-HSV activity of simple alkyl gallate derivatives, which have a 3-oxygen motif analogous to the αHTs.³³ Interest in the anti-HSV activity of gallates stems from the potent inhibitory activity of the epigallocatechin-3-O-gallate and its structural derivatives, which have multiple mechanisms of action including fusion inhibition, and they are not known to inhibit the activity of either pUL12 or pUL15.³⁴



There is little structure–function analysis for pUL12 or pUL15 inhibition outside of the tropolones. The pUL12 inhibitors emodin³⁵ and 1,2-benzisothiazolin-3-one-type³⁶ are the only non- α HT molecules known to inhibit either enzyme, and no studies have been published to date detailing synthetic chemistry-driven, targeted structure–function studies on these molecules. As a result, the potent anti-HSV activity of amide-appended α HTs – with cell-based antiviral activity on par or exceeding the clinically used anti-HSV drug acyclovir ($EC_{50}^{\text{HSV-1}} = 170 \text{ nM}$, $EC_{50}^{\text{HSV-2}} = 1.4 \text{ }\mu\text{M}$)²⁶ – coupled with our rapid strategy for synthesizing them, should be highly valuable in novel anti-HSV therapeutic development.

Conclusion

Several amide-appended α HTs have been identified with activity profiles on par with the most potent anti-HSV-1 tropolones described to date. Given the ease of their synthesis, this class warrants further investigation for HSV-1 and -2 antiviral development. Furthermore, given the broad range of biological activity and therapeutic potential of the α HT chemotype, amide-appended α HTs could be highly useful for a broader range of drug-development pursuits. For example, recent studies have shown that certain α HTs possess antiviral activity against Rift Valley fever virus, and amide-appended α HTs 1017 (**40**) 867 (**47**) and 1039 (**56**) were some of the more potent compounds.³⁷

Materials and methods

General information

All starting materials and reagents were purchased from commercially available sources and used without further purification, with the exception of THF, which was purified on a solvent purification system prior to the reaction. ¹H NMR shifts are measured using the solvent residual peak as the internal standard (CDCl₃ δ 7.26, THF-d₈ δ 3.58), and reported as follows: chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, p = pentet, dd = doublet of doublets, hept = heptet, q = quartet, m = multiplet), coupling constant (Hz), and integration. Microwave reactions were performed *via* the Biotage Initiator 2.5. Purification *via* column chromatography was performed on the Biotage Isolera Prime, with Biotage SNAP 12 g C18 cartridges, in a solvent system of acetonitrile (MeCN) and water (H₂O), with each containing 0.05% trifluoroacetic acid (TFA). Column gradients are measured in terms of column volumes (CV). Other abbreviations used: THF = tetrahydrofuran; DMF = dimethylformamide; DMSO = dimethyl sulfoxide; HATU = 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate.

Amide-appended α HT synthesis

All α HTs described in Table 1 were obtained as described previously.^{27,28} α HT-1435–1438 (**63–66**) were synthesized in an analogous fashion and a description of their synthesis follows:

4,6-Dihydroxy-2-methyl-5-oxo-*N*-(pyren-1-yl)cyclohepta-1,3,6-triene-1-carboxamide (**63**, α HT-1435). To a solution of α HT

carboxylic acid **3** (10 mg, 0.051 mmol) in THF (1.3 mL, 0.04 M) was added 2,6-lutidine (13 μ L, 0.112 mmol) and HATU (21.3 mg, 0.056 mmol). The mixture was allowed to stir for 15 min at rt under an atmosphere of Ar gas. 1-Aminopyrene (25 mg, 0.115 mmol) was then added to the solution, at which point the reaction mixture was subjected to microwave irradiation at 85 °C for 15 min. The reaction mixture was then transferred to a 125 mL separatory funnel and diluted with ethyl acetate. The organic layer was washed with a solution of saturated ammonium chloride (3 \times 20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was then redissolved in 800 μ L DMSO, loaded onto a SNAP 12 g C18 silica gel column, and subjected to reversed-phase column chromatography conditions (Biotage Isolera Prime, solvent gradient: 0–35% MeCN in H₂O (30 CV); 35–60% MeCN in H₂O (15 CV); 60–100% MeCN in H₂O (5 CV); 100% MeCN (5 CV); MeCN and H₂O each contained 0.05% TFA). Product fractions were concentrated *in vacuo* to remove MeCN, and the remaining aqueous solution was extracted with CH₂Cl₂ (3 \times 15 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to yield 1435 as a yellow oil (0.6 mg, 3% yield). ¹H NMR (400 MHz, THF-d₈) δ 10.86 (br s, 1H), 10.00 (br s, 1H), 8.55 (d, *J* = 8.3 Hz, 1H), 8.32 (d, *J* = 9.3 Hz, 1H), 8.25 (d, *J* = 8.3 Hz, 1H), 8.21–8.18 (m, 2H), 8.14 (d, *J* = 9.3 Hz, 1H), 8.12–8.05 (m, 2H), 8.00 (t, *J* = 7.6 Hz, 1H), 7.70 (s, 1H), 7.51 (s, 1H), 5.80 (br s, 1H), 2.66 (s, 3H).

4-(6-Cyclohexyl-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (**64**, α HT-1436). To a solution of α HT carboxylic acid **3** (10 mg, 0.051 mmol) in DMF (1.3 mL, 0.04 M) was added 2,6-lutidine (13 μ L, 0.112 mmol) and HATU (21.3 mg, 0.056 mmol). The mixture was allowed to stir for 15 min at rt under an atmosphere of Ar gas. 6-Cyclohexyl-1,2,3,4-tetrahydroisoquinoline (25 mg, 0.117 mmol) was then added to the solution, at which point the reaction mixture was subjected to microwave irradiation at 85 °C for 15 min. The reaction mixture was then loaded onto a SNAP 12 g C18 silica gel column, and subjected to reversed-phase column chromatography conditions (Biotage Isolera Prime, solvent gradient: 0–35% MeCN in H₂O (30 CV); 35–60% MeCN in H₂O (15 CV); 60–100% MeCN in H₂O (5 CV); 100% MeCN (5 CV); MeCN and H₂O each contained 0.05% TFA). Product fractions were concentrated *in vacuo* to remove MeCN, and the remaining aqueous solution was extracted with CH₂Cl₂ (3 \times 15 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to yield α HT-1436 (**64**) as a brown oil (2.9 mg, 14% yield). IR (ATR, ZnSe) 3439 (br), 2925 (w), 2853 (w), 1689 (s), 1636 (m), 1441 (m), 1393 (m), 1207 (s), 1140 (s), 805 (w), 726 (w) cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.54–7.46 (m, 1H), 7.38–7.29 (m, 1H), 7.19–7.09 (m, 1H), 7.08–6.81 (m, 2H), 5.04–4.78 (m, 1H), 4.44–4.26 (m, 1H), 4.21–3.84 (m, 1H), 3.57–3.41 (m, 1H), 3.03–2.95 (m, 1H), 2.91–2.74 (m, 1H), 2.54–2.47 (m, 1H), 2.47–2.32 (m, 3H), 1.93–1.83 (m, 5H), 1.81–1.73 (m, 1H), 1.54–1.33 (m, 4H).³⁸ ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 170.0, 169.7, 168.2, 158.7, 157.9, 147.7, 147.2, 137.5, 137.4, 136.4, 134.0, 133.1, 129.4, 129.0, 127.6, 127.1, 126.8, 125.9, 125.8, 125.5, 124.4, 124.3, 118.6, 118.5, 48.7, 44.7, 44.4, 40.5, 34.6, 34.6, 29.5, 28.5, 27.0, 26.2, 24.2, 24.0. HRMS (ESI⁺) *m/z* calculated for C₂₄H₂₈NO₄⁺: 394.2013. Found: 394.2016.



Dihydroxy-N-((1-(4-isopropylphenyl)cyclopentyl)methyl)-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxamide (65, α HT-1437). To a solution of α HT carboxylic acid S1 (10 mg, 0.051 mmol) in THF (1.3 mL, 0.04 M) was added 2,6-lutidine (13 μ L, 0.112 mmol) and HATU (21.3 mg, 0.056 mmol). The mixture was allowed to stir for 15 min at rt under an atmosphere of Ar gas. (1-(4-isopropylphenyl)cyclopentyl)methanamine (25 mg, 0.115 mmol) was then added to the solution, at which point the reaction mixture was subjected to microwave irradiation at 85 °C for 15 min. The reaction mixture was then transferred to a 125 mL separatory funnel and diluted with ethyl acetate. The organic layer was washed with a solution of saturated ammonium chloride (3 \times 20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was then redissolved in 800 μ L DMSO, loaded onto a SNAP 12 g C18 silica gel column, and subjected to reversed-phase column chromatography conditions (Biotage Isolera Prime, solvent gradient: 0–35% MeCN in H₂O (30 CV); 35–60% MeCN in H₂O (15 CV); 60–100% MeCN in H₂O (5 CV); 100% MeCN (5 CV); MeCN and H₂O each contained 0.05% TFA). Product fractions were concentrated *in vacuo* to remove MeCN, and the remaining aqueous solution was extracted with CH₂Cl₂ (3 \times 15 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to yield α HT-1437 (**65**) as a brown oil (7.7 mg, 38% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 1H), 7.25–7.17 (m, 4H), 5.44 (br s, 1H), 3.61 (d, *J* = 4.6 Hz, 2H), 2.87 (hept, *J* = 6.9 Hz, 1H), 2.30 (s, 3H), 2.01–1.93 (m, 4H), 1.91–1.85 (m, 2H), 1.81–1.73 (m, 2H), 1.22 (d, *J* = 6.9 Hz, 6H).

2,7-Dihydroxy-4-methyl-5-(spiro[adamantane-2,4'-piperidine]-1'-carbonyl)cyclohepta-2,4,6-trien-1-one (66, α HT-1438). To a solution of α HT carboxylic acid S1 (10 mg, 0.051 mmol) in DMF (1.3 mL, 0.04 M) was added 2,6-lutidine (13 μ L, 0.112 mmol) and HATU (21.3 mg, 0.056 mmol). The mixture was allowed to stir for 15 min at rt under an atmosphere of Ar gas. Spiro[adamantane-2,4'-piperidine]hydrochloride added (30 mg, 0.124 mmol) was then to the solution, at which point the reaction mixture was subjected to microwave irradiation at 85 °C for 15 min. The reaction mixture was then loaded onto a SNAP 12 g C18 silica gel column and subjected to reversed-phase column chromatography conditions (Biotage Isolera Prime, solvent gradient: 0–35% MeCN in H₂O (30 CV); 35–60% MeCN in H₂O (15 CV); 60–100% MeCN in H₂O (5 CV); 100% MeCN (5 CV); MeCN and H₂O each contained 0.05% TFA). Product fractions were concentrated *in vacuo* to remove MeCN, and the remaining aqueous solution was extracted with CH₂Cl₂ (3 \times 15 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to yield α HT-1438 (**66**) as a brown oil (2.8 mg, 14% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.46 (s, 1H), 7.27 (s, 1H), 3.82–3.64 (m, 2H), 3.24–3.11 (m, 2H), 2.41 (s, 3H), 2.11–2.03 (m, 2H), 1.96–1.76 (m, 6H), 1.73–1.55 (m, 10H).

Cells and viruses

Vero cells were originally obtained from D. Knipe and were maintained in Dulbecco's modified Eagle's medium supplemented to contain 3% bovine growth serum, 3% newborn calf serum, and 100 IU per mL penicillin/0.1 mg per mL

streptomycin. HSV-1 and HSV-2 strains were de-identified, minimally passaged clinical isolates obtained from the Saint Louis University Hospital Lab.

HSV replication inhibition assay

Vero cells were seeded into 24-well plates and used when monolayers became confluent. Compounds were diluted in PBS supplemented to contain 2% newborn calf serum and 2 mM L-glutamine and added to cell monolayers in duplicate. HSV-2 was diluted in supplemented PBS medium and added so that the final concentrations of compound were 50 μ M or 5 μ M per well and of virus were 2 \times 10⁴ PFU per well. The cells were incubated at 37 °C for 1 h, the virus-containing inoculum was removed, the wells were washed once in PBS, and compound (50 μ M or 5 μ M) in supplemented DMEM was added. Cells were incubated at 37 °C for an additional 24 h, and the plates were then inspected by phase-contrast microscopy for toxicity. Cells in wells showing no obvious toxicity compared with DMSO-control wells were frozen at –80 °C for later determination of virus titers by standard plaque assay on Vero cells. Cell monolayers were fixed with methanol, stained with Giemsa, and plaques were visualized and counted under low power magnification. The 50% effective concentration (EC₅₀) was determined as described above except that serial dilutions of the compounds were employed in 96-well plates. Values were calculated with GraphPad Prism using the three-parameter log(inhibitor)-versus-response algorithm with the bottom value set to zero. Representative dose-response curves can be found on Page s4 of the ESI.†

Cytotoxicity assay

Vero cells were seeded in 96-well plates and incubated in DMEM as indicated above. The compounds were serially diluted in medium containing 1% DMSO and added to the cells 24 h after plating, with each concentration tested in duplicate. Twenty-four or 48 h after compound addition, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was added, the cultures were incubated for 90 min, and the absorbance was read at 490 nm. 50% cytotoxic concentration (CC₅₀) values were calculated with GraphPad Prism using the four-parameter variable slope algorithm with the bottom value set to zero. Representative dose-response curves can be found on Page s5 of the ESI.†

Author contributions

Conceptualization, L. A. M. and R. P. M.; chemical synthesis, A. J. B., D. V. S., D. M. K., R. P. M.; biological studies, A. G. C., A. J. Y., H. E. W., L. A. M.; writing, review and editing, L. A. M. and R. P. M. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

LAM and RPM are inventors on patents describing the HSV antiviral activity of α HTs.



Acknowledgements

This research was funded by the National Institutes of Health, grant number SC1-GM111158 (R. P. M.) and the Pershing Trust (L. A. M.). The authors would like to thank David Knipe (Harvard) for providing Vero cells, and John Tavis and his lab (SLU) for help with the organization and maintenance of the α -HT library used herein.

Notes and references

- R. J. Whitley, Herpes Simplex Viruses, in *Fields Virology*, ed. D. Knipe and P. Howley, Lippincott Williams & Wilkins, Philadelphia, PA, US, 4th edn, 2001, vol. 2, pp. 2461–2509.
- C. James, M. Harfouche, N. J. Welton, K. M. Turner, L. J. Abu-Raddad, S. L. Gottlieb and K. J. Looker, *Bull. World Health Organ.*, 2020, **98**, 315–329.
- K. J. Looker, A. S. Magaret, K. M. Turner, P. Vickerman, S. L. Gottlieb and L. M. Newman, *PLoS One*, 2015, **10**, e114989.
- (a) S. G. Pinninti and D. W. Kimberlin, *Am. J. Perinatol.*, 2013, **30**, 113–119; (b) N. Dabestani, D. Katz, J. Dombrowski, A. Magaret, A. Wald and C. Johnston, *Sex. Transm. Dis.*, 2019, **46**, 795–800.
- C. Johnston, M. Saracino, S. Kuntz, A. Magaret, S. Selke, M. L. Huang, J. T. Schiffer, D. M. Koelle, L. Corey and A. Wald, *Lancet*, 2012, **379**, 641–647.
- (a) S. H. James and M. N. Prichard, *Curr. Opin. Virol.*, 2014, **8**, 54–61; (b) J. Piret and G. Boivin, *Rev. Med. Virol.*, 2014, **24**, 186–218; (c) J. Piret and B. Guy, *Antimicrob. Agents Chemother.*, 2011, **55**, 459–472; (d) M. J. Lee, T. H. Bacon and J. J. Leary, *Clin. Infect. Dis.*, 2004, **39**, S248–S257.
- (a) R. A. V. Hodge and H. J. Field, *Adv. Pharmacol.*, 2013, **67**, 1–38; (b) S. K. Mamidyala and S. V. Firestone, *Expert Opin. Ther. Pat.*, 2006, **16**, 1463–1480; (c) K. Szczubiatka, K. Pyrc and M. Nowakowska, *RSC Adv.*, 2016, **6**, 1058–1075.
- (a) C. S. Crumpacker and P. A. Schaffer, *Nat. Med.*, 2002, **8**, 327–328; (b) G. Kleymann, R. Fischer, U. A. K. Betz, M. Hendrix, W. Bender, U. Schneider, G. Handke, P. Eckenberg, G. Hewlett, V. Pevzner, J. Baumeister, O. Weber, K. Henninger, J. Keldenich, A. Jensen, J. Kolb, U. Bach, A. Popp, J. Mäben, I. Frappa, D. Haebich, O. Lockhoff and H. Rübsamen-Waigmann, *Nat. Med.*, 2002, **8**, 392–398; (c) J. J. Crute, C. A. Grycon, K. D. Hargrave, B. Simoneau, A.-M. Faucher, G. Bolger, P. Kibler, M. Liuzzi and M. G. Cordingley, *Nat. Med.*, 2002, **8**, 386–391.
- A. Manikowski, A. Verri, A. Lossani, B. M. Gebhardt, J. Gambino, F. Focher, S. Spadari and G. E. Wright, *J. Med. Chem.*, 2005, **48**, 3919–3929.
- T. E. Antoine, P. J. Park and D. Shukla, *Rev. Med. Virol.*, 2013, **23**, 194–208.
- (a) Z. Jiang, Q. You and X. Zhang, *Eur. J. Med. Chem.*, 2019, **165**, 172–197; (b) S. M. A. Cohen, *Acc. Chem. Res.*, 2017, **50**, 2007–2016.
- (a) R. A. Bentley, *Nat. Prod. Rep.*, 2008, **25**, 118–138; (b) N. Liu, W. Song and W. Tang, *Tetrahedron*, 2014, **70**, 9281–9305; (c) H. Guo, D. Roman and C. Beemelmans, *Nat. Prod. Rep.*, 2019, **36**, 1137–1155.
- (a) S. N. Ononye, M. D. VanHeyst, E. Z. Oblak, W. Zhou, M. Ammar, A. C. Anderson and D. L. Wright, *ACS Med. Chem. Lett.*, 2013, **4**, 757–761; (b) J. L. Fullagar, A. L. Garner, A. Struss, J. A. Day, D. P. Martin, J. Yu, X. Cai, K. D. Janda and S. M. Cohen, *Chem. Commun.*, 2013, **49**, 3197–3199; (c) A. S. Grillo, A. M. SantaMaria, M. D. Kafina, A. G. Cioffi, N. C. Huston, M. Han, Y. A. Seo, Y. Y. Yien, C. Nardone, A. V. Menon, J. Fan, D. C. Svoboda, J. B. Anderson, J. D. Hong, B. G. Nicolau, K. Subedi, A. A. Gewirth, M. Wessling-Resnick, J. Kim, B. H. Paw and M. D. Burke, *Science*, 2017, **356**, 608–616.
- J. E. Tavis, H. Wang, A. E. Tollefson, B. Ying, M. Korom, X. Cheng, F. Cao, K. L. Davis, W. S. W. Wold and L. A. Morrison, *Antimicrob. Agents Chemother.*, 2014, **58**, 7451–7461.
- (a) E. A. Semenova, A. A. Johnson, C. Marchand, D. A. Davis, R. Yarchoan and Y. Pommier, *Mol. Pharmacol.*, 2006, **69**, 1454–1460; (b) S. F. Martin, B. C. Follows, P. J. Hergenrother and C. L. Franklin, *J. Org. Chem.*, 2000, **65**, 4509–4514; (c) S. R. Piettre, A. Ganzhorn, J. Hoflack, K. Islam and J.-M. Hornsperger, *J. Am. Chem. Soc.*, 1997, **119**, 3201–3204; (d) N. E. Allen, W. E. Alborn, J. N. Hobbs Jr and J. H. A. Kirst, *Antimicrob. Agents Chemother.*, 1982, **22**, 824–831; (e) For a review, see: C. M. Meck, M. P. D'Erasmus, D. R. Hirsch and R. P. Murelli, *Med. Chem. Commun.*, 2014, **5**, 842–852.
- T. Masaoka, H. Zhao, D. R. Hirsch, M. P. D'Erasmus, C. M. Meck, B. Varnado, A. Gupta, M. J. Meyers, J. D. Baines, J. A. Beutler, R. P. Murelli, L. Tang and S. F. J. Le Grice, *Biochemistry*, 2016, **55**, 809–819.
- L. M. Grady, R. Szczepaniak, R. P. Murelli, T. Masaoka, S. F. J. Le Grice, D. L. Wright and S. K. Weller, *J. Virol.*, 2017, **91**, e01380.
- (a) P. M. Beard, N. S. Taus and J. D. Baines, *J. Virol.*, 2002, **76**, 4785–4791; (b) D. Yu and S. Weller, *J. Virol.*, 1998, **72**, 7428–7439.
- (a) F. Foolad, S. L. Aitken and R. F. Chemaly, *Expert Rev. Clin. Pharmacol.*, 2018, **10**, 931–941; (b) L. Yang, Q. Yang, M. Wang, R. Jia, S. Chen, D. Zhu, M. Liu, Y. Wu, X. Zhao, S. Zhang, Y. Liu, Y. Yu, L. Zhang, X. Chen and A. Cheng, *Viruses*, 2019, **11**, 219.
- J. N. Goldstein and S. K. Weller, *Virology*, 1998, **244**, 442–457.
- (a) J. Zinser, S. Henkel and B. Fohlsch, *Eur. J. Org. Chem.*, 2004, 1344–1346; (b) M. G. Banwell and M. P. Collis, *J. Chem. Soc., Chem. Commun.*, 1991, 1343–1345.
- G. Sennari, R. Saito, T. Hirose, M. Iwatsuki, A. Ishiyama, R. Hokari, K. Otoguro, S. Omura and T. Sunazuka, *Sci. Rep.*, 2017, **7**, 7259.
- (a) J. Didierjean, C. Isel, F. Querre, J.-F. Mouscadet, A.-M. Aubertin, J.-Y. Valnot, S. R. Piettre and R. Marquet, *Antimicrob. Agents Chemother.*, 2005, **49**, 4884–4894; (b) S. R. Piettre, C. Andre, M.-C. Chanal, J.-B. Ducep, B. Lesur, F. Piriou, P. Raboisson, J.-M. Rondeau and C. Schelcher, *J. Med. Chem.*, 1997, **40**, 4208–4221.



- 24 S. Chung, D. M. Himmel, J.-K. Jiang, K. Wojtak, J. D. Bauman, J. W. Rausch, J. A. Wilson, J. A. Beutler, C. J. Thomas, E. Arnold and S. F. J. Le Grice, *J. Med. Chem.*, 2011, **54**, 4462–4473.
- 25 C. Meck, N. Mohd and R. P. Murelli, *Org. Lett.*, 2012, **14**, 5988–5991.
- 26 P. J. Ireland, J. E. Tavis, M. P. D'Erasmus, D. R. Hirsch, R. P. Murelli, M. M. Cadiz, B. S. Patel, A. K. Gupta, T. C. Edwards, M. Korom, E. A. Moran and L. A. Morrison, *Antimicrob. Agents Chemother.*, 2016, **60**, 2140–2149.
- 27 A. J. Berkowitz, A. D. Franson, A. G. Casals, K. A. Donald, A. J. Yu, A. K. Garimallaprabhakaran, L. A. Morrison and R. P. Murelli, *Med. Chem. Commun.*, 2019, **10**, 1173–1176.
- 28 A. J. Berkowitz, R. G. Abdelmessih and R. P. Murelli, *Tetrahedron Lett.*, 2018, **59**, 3026–3028.
- 29 Q. Li, E. Lomonosoca, M. Donlin, F. Cao, A. O'Dea, B. Milleson, A. J. Berkowitz, J.-C. Baucom, J. P. Stasiak, D. V. Schiavone, R. G. Abdelmessih, A. Lyubimova, A. J. Fraboni, L. P. Bejcek, J. A. Villa, E. Gallicchio, R. P. Murelli and J. E. Tavis, *Antiviral Res.*, 2020, **177**, 104777.
- 30 R. Mannhold, G. I. Poda, C. Ostermann and I. V. Tetko, *J. Pharm. Sci.*, 2009, **98**, 861–893.
- 31 (a) J. P. Stasiak, A. Grigoryan and R. P. Murelli, *Tetrahedron Lett.*, 2019, **60**, 1643–1645; (b) N. Yui, *Sci. Rep. Tohoku Univ. First Ser.*, 1956, **40**, 114–120.
- 32 D. H. Katz, J. F. Marcelletti, M. H. Khalil, L. E. Pope and L. R. Katz, *Proc. Natl. Acad. Sci. U. S. A.*, 1991, **88**, 10825–10829.
- 33 M. Uozaki, H. Yamasaki, Y. Katsuyama, M. Higuchi, Y. Higuti and A. H. Koyama, *Antiviral Res.*, 2007, **73**, 85–91.
- 34 K. Kaihatsu, M. Yamabe and Y. Ebara, *Molecules*, 2018, **23**, 2475.
- 35 C.-Y. Hsiang and T.-Y. Ho, *Br. J. Pharmacol.*, 2008, **155**, 227–235.
- 36 J. C. Bronstein and P. C. A. Weber, *Anal. Biochem.*, 2001, **293**, 239–245.
- 37 E. Geerling, V. Murphy, M. C. Mai, E. T. Stone, A. G. Casals, M. Hassert, A. T. O'Dea, F. Cao, M. J. Donlin, M. Elagawany, B. Elgendy, V. Pardali, E. Giannakopoulou, G. Zoidis, D. V. Schavone, N. B. Agyemang, R. P. Murelli, J. E. Tavis, A. K. Pinto and J. D. Brien, *PLoS One*, 2022, **17**, e0274266.
- 38 Complex splitting arises from the molecule's atropdiastereotopicity. This is due to hindered rotation about the Ar-C(O) bond combined with the presence of inequivalent *E* and *Z* amide rotamers.

